These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 8873230)
1. Pharmaceutical analysis of the oral iron chelator deferiprone (DMHP,L1). Lange R; Lameijer W; Slijkhuis C; de Kaste D Pharm World Sci; 1996 Aug; 18(4):142-7. PubMed ID: 8873230 [TBL] [Abstract][Full Text] [Related]
2. Long-term treatment of transfusional iron overload with the oral iron chelator deferiprone (L1): a Dutch multicenter trial. Kersten MJ; Lange R; Smeets ME; Vreugdenhil G; Roozendaal KJ; Lameijer W; Goudsmit R Ann Hematol; 1996 Nov; 73(5):247-52. PubMed ID: 8959943 [TBL] [Abstract][Full Text] [Related]
3. Results of long-term deferiprone (L1) therapy: a report by the International Study Group on Oral Iron Chelators. al-Refaie FN; Hershko C; Hoffbrand AV; Kosaryan M; Olivieri NF; Tondury P; Wonke B Br J Haematol; 1995 Sep; 91(1):224-9. PubMed ID: 7577638 [TBL] [Abstract][Full Text] [Related]
4. Studies on an oral iron chelator: 1,2-dimethyl-3-hydroxy-pyrid-4-one (DMHP). Mechanism of intestinal absorption in rabbits. Railkar AM; Awni WM; Camp RJ; Rahman YE J Pharm Pharmacol; 1993 May; 45(5):400-5. PubMed ID: 8099956 [TBL] [Abstract][Full Text] [Related]
5. Crystal structures of a new oral iron chelator, 1,2-dimethyl-3-hydroxy-4-pyridone, and its solvates with acetic acid and formic acid. Chan HK; Ghosh S; Venkataram S; Rahman YE; Grant DJ J Pharm Sci; 1992 Apr; 81(4):353-8. PubMed ID: 1501073 [TBL] [Abstract][Full Text] [Related]
6. Studies of an oral iron chelator: 1,2-dimethyl-3-hydroxy-pyrid-4-one. I. Iron excretion in rats: development of a new rapid microwave method for iron analysis in faeces. Venkataram S; Rahman YE Br J Haematol; 1990 Jun; 75(2):274-7. PubMed ID: 2372514 [TBL] [Abstract][Full Text] [Related]
7. The efficacy of oral deferiprone in acute iron poisoning. Berkovitch M; Livne A; Lushkov G; Segal M; Talmor C; Bentur Y; Klein J; Koren G Am J Emerg Med; 2000 Jan; 18(1):36-40. PubMed ID: 10674529 [TBL] [Abstract][Full Text] [Related]
8. Iron chelation therapy. Hoffbrand AV; Wonke B J Intern Med Suppl; 1997; 740():37-41. PubMed ID: 9350180 [TBL] [Abstract][Full Text] [Related]
9. [Treatment of iron overload states with oral administration of the chelator agent, L1 (Deferiprone)]. Cermák J; Brabec V Vnitr Lek; 1994 Sep; 40(9):586-90. PubMed ID: 7975362 [TBL] [Abstract][Full Text] [Related]
10. Recent developments in iron chelation therapy. Cario H; Janka-Schaub G; Janssen G; Jarisch A; Strauss G; Kohne E Klin Padiatr; 2007; 219(3):158-65. PubMed ID: 17525910 [TBL] [Abstract][Full Text] [Related]
11. Assessment of the effect of the oral iron chelator deferiprone on asymptomatic Plasmodium falciparum parasitemia in humans. Thuma PE; Olivieri NF; Mabeza GF; Biemba G; Parry D; Zulu S; Fassos FF; McClelland RA; Koren G; Brittenham GM; Gordeuk VR Am J Trop Med Hyg; 1998 Mar; 58(3):358-64. PubMed ID: 9546419 [TBL] [Abstract][Full Text] [Related]
12. New concepts of iron and aluminium chelation therapy with oral L1 (deferiprone) and other chelators. A review. Kontoghiorghes GJ Analyst; 1995 Mar; 120(3):845-51. PubMed ID: 7741239 [TBL] [Abstract][Full Text] [Related]
13. Chelation therapy in patients with thalassemia using the orally active iron chelator deferiprone (L1). Rombos Y; Tzanetea R; Konstantopoulos K; Simitzis S; Zervas C; Kyriaki P; Kavouklis M; Aessopos A; Sakellaropoulos N; Karagiorga M; Kalotychou V; Loukopoulos D Haematologica; 2000 Feb; 85(2):115-7. PubMed ID: 10681716 [TBL] [Abstract][Full Text] [Related]
14. 1,2-Dimethyl-3-hydroxypyrid-4-one, an orally active chelator for treatment of iron overload. Kontoghiorghes GJ; Aldouri MA; Sheppard L; Hoffbrand AV Lancet; 1987 Jun; 1(8545):1294-5. PubMed ID: 2884415 [TBL] [Abstract][Full Text] [Related]
15. Efficacy of deferiprone in the treatment of acute iron intoxication in rats. Fassos FF; Berkovitch M; Daneman N; Koren L; Cameron RG; Klein J; Falcitelli C; St Louis P; Daneman R; Koren G J Toxicol Clin Toxicol; 1996; 34(3):279-87. PubMed ID: 8667465 [TBL] [Abstract][Full Text] [Related]
16. Effective chelation of iron in beta thalassaemia with the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one. Kontoghiorghes GJ; Aldouri MA; Hoffbrand AV; Barr J; Wonke B; Kourouclaris T; Sheppard L Br Med J (Clin Res Ed); 1987 Dec; 295(6612):1509-12. PubMed ID: 3122880 [TBL] [Abstract][Full Text] [Related]
17. The design and development of deferiprone (L1) and other iron chelators for clinical use: targeting methods and application prospects. Kontoghiorghes GJ; Pattichis K; Neocleous K; Kolnagou A Curr Med Chem; 2004 Aug; 11(16):2161-83. PubMed ID: 15279556 [TBL] [Abstract][Full Text] [Related]
18. Deferasirox for the treatment of iron overload associated with regular blood transfusions (transfusional haemosiderosis) in patients suffering with chronic anaemia: a systematic review and economic evaluation. McLeod C; Fleeman N; Kirkham J; Bagust A; Boland A; Chu P; Dickson R; Dundar Y; Greenhalgh J; Modell B; Olujohungbe A; Telfer P; Walley T Health Technol Assess; 2009 Jan; 13(1):iii-iv, ix-xi, 1-121. PubMed ID: 19068191 [TBL] [Abstract][Full Text] [Related]
19. Systematic comparison of the mono-, dimethyl- and trimethyl 3-hydroxy-4(1H)-pyridones - Attempted optimization of the orally active iron chelator, deferiprone. Xie YY; Lu Z; Kong XL; Zhou T; Bansal S; Hider R Eur J Med Chem; 2016 Jun; 115():132-40. PubMed ID: 27014847 [TBL] [Abstract][Full Text] [Related]